VNS201B (vagus nerve stimulation system)

2024: Entering the Russian market

In October 2024, the Russian company LLC Motor Engineering NEMO announced the receipt of indefinite registration certificates for medical devices included in the company's vagus nerve stimulation system (VNS). Rishena These devices are designed to treat pharmacoresistant, epilepsies which affects about 50 million people worldwide.

According to Газета.ru, Rishena Medical is a Chinese company specializing in the development, production and sale of active implantable medical devices for neurostimulation of the vagus nerve. VNS therapy technology, used in the world since 1990, involves the implantation of an electrode around the nerve through which information enters the brain. A stimulant placed under the skin sends anti-epileptic impulses through the nerve to the brain, preventing the development of convulsive seizures.

𝓲

Rishena

VNS therapy is particularly effective in cases where drug treatment does not produce results and surgery is impractical. An important advantage of this method is the possibility of its use both in children over six years of age and in adult patients.

The VNS201B device from Rishena, planned to enter the Russian market, is distinguished by the presence of two programmers: for a doctor and for a patient. This allows remote adjustment of stimulation parameters including amplitude, duration and pulse frequency. The stimulant is characterized by compact size, light weight (27 grams) and complete tightness.

Thanks to the 1800 mAh battery and low energy consumption, the device is capable of providing stable stimulation for up to 10 years, which significantly increases the quality of life of patients with epilepsy, "said Andrey Davidyuk, technical director of Motorika NEMO LLC.[1]

Notes